Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Novartis-Genentech's Urticaria drug Xolair gets US FDA approval The US Food and Drug Administration (FDA) has approved Novartis and Genentech's Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), an unpredictable and debilitating skin disease that is called as chronic spontaneous urticaria (CSU) outside of the US. Drug Research > Drug Delivery > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Janssen’s MCD drug SYLVANT gets FDA approval
24 April 2014 | By PBR Staff Writer
Janssen Biotech has received approval from the US Food and Drug Administration (FDA) for its SYLVANT (siltuximab) as a treatment for patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Drug Research > Drug Delivery > News
Sagent reintroduces Adenosine injection with improved prefilled plastic syringes
22 April 2014 | By PBR Staff Writer
US-based Sagent Pharmaceuticals has reintroduced Adenosine Injection, USP, an antiarrhythmic agent, with improved prefilled plastic syringes.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Boehringer Ingelheim receives orphan drug designation for volasertib in US and EU
21 April 2014 | By PBR Staff Writer
Boehringer Ingelheim Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) and the European Commission for its volasertib for the treatment of acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
Islet Sciences reports results from two Phase IIb clinical studies for type 2 diabetics drug
17 April 2014 | By PBR Staff Writer
Islet Sciences and BHV Pharma have reported positive data from the two 12-week Phase IIb clinical studies of SGLT2 inhibitor remogliflozin etabonate in type 2 diabetics.
Drug Research > Drug Discovery & Development > News